Showing results (411-420 of 463) with videos related to
Sort By:
Pageof 47
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 22, 2018
A randomised, controlled clinical trial of narrowband UVB phototherapy for clinically isolated syndrome: The PhoCIS studyPrue H Hart, Anderson P Jones, Stephanie Trend, et al.Scientific Reports|May 30, 2019
Short-term changes in frequencies of circulating leukocytes associated with narrowband UVB phototherapy in people with clinically isolated syndromeStephanie Trend, Anderson P Jones, Lilian Cha, et al.Clinical Immunology (Orlando, Fla.)|January 15, 2016
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapiesFiona C McKay, Prudence N Gatt, Nicole Fewings, et al.Data in Brief|March 10, 2017
Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosisN Fewings, P N Gatt, F C McKay, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|October 12, 2018
New Irreversible α-l-Iduronidase Inhibitors and Activity-Based ProbesMarta Artola, Chi-Lin Kuo, Stephen A McMahon, et al.Journal of Autoimmunity|January 9, 2017
The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosisN L Fewings, P N Gatt, F C McKay, et al.Annals of Clinical and Translational Neurology|July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluidMolly Reynolds, Irene Tan, Kristy Nguyen, et al.The Pharmacogenomics Journal|March 23, 2016
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association studyS Mahurkar, M Moldovan, V Suppiah, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Pageof 47